a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent for use in treating or preventing a symptom caused by type 2 Porcine Reproductive and Respiratory Syndrome (PRRS) virus infection in a porcine animal.

In a further aspect of the present disclosure, there is provided a use of an immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 98% identical to a sequence selected from the group of SEQ ID NO: 9, SEQ ID NO: 12, and SEQ ID NO: 13; and
a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent in the manufacture of a medicament for treating or preventing a symptom caused by type 2 Porcine Reproductive and Respiratory Syndrome (PRRS) virus infection in a porcine animal.

In another aspect of the present disclosure, there is provided a vaccine comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is ATCC Deposit No. PTA-122674.

In yet another aspect of the present disclosure, there is provided a vaccine comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is ATCC Deposit No. PTA-122674, for use in treating or preventing a symptom caused by type 2 Porcine Reproductive and Respiratory Syndrome (PRRS) virus infection in a porcine animal.

In a further aspect of the present disclosure, there is provided a use of a vaccine comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is ATCC Deposit No. PTA-122674, in the manufacture of a medicament for treating or preventing a symptom caused by type 2 Porcine Reproductive and Respiratory Syndrome (PRRS) virus infection in a porcine animal.

DESCRIPTION

The present invention provides for a modified, live Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine virus strain, wherein the consensus complementary DNA sequence of said PRRS strain is at least 90% identical to a sequence selected from the group of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13. Preferably, the modified, live strain could have a consensus complementary DNA sequence that is at least 95% identical to a sequence selected from the group of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13. More preferably, the modified, live strain could also have a consensus complementary DNA sequence that is at least 98% identical

WHAT IS CLAIMED IS:

1. A modified, live Porcine Reproductive and Respiratory Syndrome (PRRS) virus strain, wherein the consensus complementary DNA sequence of said PRRS strain is at least 95% identical to a sequence selected from the group of SEQ ID NO: 9, SEQ ID NO: 12, and SEQ ID NO: 13.
2. The modified, live PRRS virus strain of Claim 1, wherein the consensus complementary DNA sequence of said PRRS strain is at least 98% identical to a sequence selected from the group of SEQ ID NO: 9, SEQ ID NO: 12, and SEQ ID NO: 13.
3. The modified, live PRRS virus strain of Claim 1, wherein said PRRS strain is ATCC Deposit No. PTA-122674.
4. The PRRS strain of Claim 1, wherein said PRRS virus strain is passaged at least 83 times in tissue culture cells.
5. The PRRS strain of Claim 1, wherein said PRRS virus strain is passaged 83 times in tissue culture cells.
6. An immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 95% identical to a sequence selected from the group of SEQ ID NO: 9, SEQ ID NO: 12, and SEQ ID NO: 13; and
a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent.
7. The immunogenic composition of Claim 6, wherein the consensus complementary DNA sequence is at least 98% identical to a sequence selected from the group of SEQ ID NO: 9, SEQ ID NO: 12, and SEQ ID NO: 13.
8. The immunogenic composition of Claim 6, wherein the modified, live PRRS virus strain is ATCC Deposit No. PTA-122674.
9. The immunogenic composition of Claim 6, further comprising an adjuvant.

10. An immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 98% identical to a sequence selected from the group of SEQ ID NO: 9, SEQ ID NO: 12, and SEQ ID NO: 13; and a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent for use in treating or preventing a symptom caused by type 2 Porcine Reproductive and Respiratory Syndrome (PRRS) virus infection in a porcine animal.

11. Use of an immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 98% identical to a sequence selected from the group of SEQ ID NO: 9, SEQ ID NO: 12, and SEQ ID NO: 13; and a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent in the manufacture of a medicament for treating or preventing a symptom caused by type 2 Porcine Reproductive and Respiratory Syndrome (PRRS) virus infection in a porcine animal.

12. A vaccine comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is ATCC Deposit No. PTA-122674.

13. A vaccine comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is ATCC Deposit No. PTA-122674, for use in treating or preventing a symptom caused by type 2 Porcine Reproductive and Respiratory Syndrome (PRRS) virus infection in a porcine animal.

14. Use of a vaccine comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is ATCC Deposit No. PTA-122674, in the manufacture of a medicament for treating or preventing a symptom caused by type 2 Porcine Reproductive and Respiratory Syndrome (PRRS) virus infection in a porcine animal.

15. The vaccine or use of Claim 13 or Claim 14, wherein the PRRS virus infection is caused by a virulent type 2 PRRS virus heterologous to the modified, live PRRS virus strain in the vaccine.